natgillin/translations-raw huggingface dataset:
applying one or more meshes to the semimanufactured component of the upper having said membrane coupled thereto, without compromising vapor permeation of the membrane, wherein the one or more meshes are made of synthetic material and/or other protective elements or supporting elements which allow the passage of sealing materials. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da se prema njemu na gornjište (12) postavlja navedena membrana (13) koja se spaja, bez ugrožavanja njezine paropropusnosti, na jednu ili više mrežica izrađenih od sintetičkih materijala i/ili drugih zaštitnih elemenata ili potpornih elemenata koji omogućuju prolaz materijala za brtveno spajanje.
The audio decoding method of any of the preceding examples, wherein the decorrelated signal is a single-channel signal and wherein said output signal is formed by including no more than one decorrelated signal channel into said linear combination of the downmix signal and the decorrelated signal. 
Postupak audio dekodiranja u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je dekorelirani signal dvokanalni signal, te što se navedeni izlazni signal formira uključivanjem najviše dva kanala dekoreliranog signala u navedenu linearnu kombinaciju signala nakon miješanja prema dolje i dekoreliranog signala.
The bed arrangement of claim 9, wherein control unit is further arranged to store, when the set of lying positions is defined or redefined, sensor data from said sensors corresponding to said predefined lying positions, and to use said stored data for distinguishing between the predefined lying positions when in an operative mode. 
Krevet u skladu s patentnim zahtjevom 8, naznačen time što je kontrolna jedinica dodatno prilagođena za spremanje, kada je skup ležećih položaja definiran ili redefiniran, senzorski podaci iz navedenih senzora koji odgovaraju navedenim unaprijed definiranim ležećim položajima i da se koriste navedeni pohranjeni podaci za razlikovanje unaprijed definiranih ležećih položaja u operativnom režimu.
The process of claim 1, further comprising a step of curing the coated core particles. 
Postupak sukladno zahtjevu 1, naznačeno time, da se nadalje sadrži korak stvrdnjavanja obloženih čestica jezgre.
a parylene coating on the outer surface of the body; and 
(b) parilensku oblogu na vanjskoj površini tijela; i
represents a nitrogen atom or CH; one of X1 to X5 represents a nitrogen atom and the remaining four represent CR2; 
Ri predstavlja dušikov atom ili CH; jedan od X, do Xs5 predstavlja dušikov atom i preostala četiri predstavljaju CR»;
A large-scale process for preparing a boronic ester compound of formula (I): wherein: 
(c) osiguranje otopina koja sadrži (i) ester organoborne kiseline formule (177):
the alkyl, alkenyl, and alkynyl portion of such substituents optionally is substituted with one or two substituents independently selected from the group consisting of carboxy, halo, oxo, amino, alkyloxycarbonyl, alkylcarbonyloxy, hydroxy, alkyloxy, carbocyclyl, heterocyclyl, and cyano, wherein: the amino optionally is substituted with one or two substituents independently selected from the group consisting of alkyl and alkyloxy, wherein: the alkyl optionally is substituted with one or more hydroxy; and 
alkil, alkenil i alkinil dio od takvih supstituenata je opcijski supstituiran s jednim ili dva supstituenta neovisno odabranima iz skupine koju sačinjavaju karboksi, halo, okso, amino, alkiloksikarbonil, alkilkarboniloksi, hidroksi, alkiloksi, karbociklil, heterociklil i cijano, gdje: amino je opcijski supstituiran s jednim ili dva supstituenta neovisno odabranima iz skupine koju sačinjavaju alkil i alkiloksi, gdje: alkil je opcijski supstituiran s jednim ili više hidroksi; i svaki RK je neovisno odabran iz skupine koju sačinjavaju aminosulfonil i alkilsulfonil, pri čemu:
The compound of claim 8, which is: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 
[image] [image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer.
These uses, methods and medicaments are preferably for the treatment of a cancer, particularly those with solid tumours, such as renal cell carcinoma or melanoma, which cancer may be metastatic. 
Ove uporabe, metode i medikamenti su pogodno za liječenje raka, posebno onih sa solidnim tumorima, kao što je karcinom bubrežnih stanica ili melanom, koji rak može biti metastatski.
The ship according to claim 8, characterized by the fact that said second face (3) is made up of two substantially flat upper (3a) and lower (3b) facets which form an obtuse angle dihedron open toward the rear. 
Brod prema zahtjevu 8, naznačen time da je spomenuta druga strana (3) izrađena od dvije vrlo ravne plohe, gornje (3a) i donje (3b), koje tvore dihedron s tupim kutom otvorenim prema natrag.
A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a compound of any one of claims 1 to 10, or a stereoisomer, a tautomer, a pharmaceutically acceptable salt or a solvate thereof. 
11. Farmaceutska kompozicija sastoji se od: farmaceutski prihvatljivog nosača 1 spoja iz bilo kojeg od patentnih zahtjeva 1 do 10, ili stereoizomera, tautomera, farmaceutski prihvatljive soli ili solvata tog spoja.
The antibody, immunoconjugate, bispecific or multispecific molecule, pharmaceutical composition or expression vector for use according to any one of claims 21 to 23, wherein said use comprises administration of one or more further therapeutic agents to the subject. 
Protutijelo, imunokonjugat, farmaceutski pripravak, bispecifična ili multispecifična molekula za uporabu u skladu s patentnim zahtjevima 16 do 21, naznačeno time što metoda uključuje primjenu jednog ili više daljnjih terapijskih sredstava subjektu.
either transmits or forwards a considered data packet, 
Ili prenosi 1li prosljeđuje razmotreni paket podataka,
This section with an enlarged diameter 27 also serves the purpose of stiffening the guide to plate engagement zone. 
Ovaj presjek s povećanim promjerom 27 također služi za ukrućivanje vodilice prema zoni spajanja s pločom.
The flask was cooled to 0 °C and thionyl chloride (36.7 g, 309 mmol) was added via syringe over a period of 5 min. 
Reakcijska tikvica je ohlađena na 0% C i dodavan je tionil klorid (36.7 g, 309 mmol) putem igle tijekom razdoblja od 5 minuta.
The compound as recited in Claim 1 wherein said chronic hyperkinetic movement disorder is tardive dynkinesia. 
Spoj za uporabu prema zahtjevu 1, naznačen time da navedeni kronični poremećaj hiperkinetičkog pokreta je tardivna diskinezija.
The crystalline sodium salt according to claim 2, wherein the X-ray powder diffraction pattern further comprises peaks at 5.4 and 8.7 degrees 2θ (±0.2 degrees 2θ) when measured using CuKa radiation. 
Kristalna natrijeva sol prema zahtjevu 4, naznačena time, da uzorak difrakcije praha X-zraka nadalje obuhvaća vršne vrijednosti na 5,4 1 8,7 stupnjeva 20 (+ 0,2 stupnjeva 20) kada se mjeri uporabom radijacije CuKa.
A composition according to claim 1, obtainable by the method of claim 7, wherein said composition comprises a bispecific ligand that is capable of binding to a surface component of said minicells and to a surface component of a non-phagocytic mammalian cell. 
Kompozicija prema Zahtjevu 1, dobijena postupkom iz Zahtjeva 7, naznačena time, što spomenuta kompozicija sadrži neki bispecifični ligand koji se je u stanju vezati za neku komponentu na površini neke ne-fagocitne stanice sisavaca.
a first effector sequence of at least 17 nucleotides in length; a first effector complement sequence; a second effector sequence of at least 17 nucleotides in length; and a second effector complement sequence; wherein each effector sequence is at least 85% complementary to the predicted transcript of a target sequence, and wherein at least one of the effector sequences comprises any 10 or more contiguous nucleotides of the sequence set forth in SEQ ID NO: 9.The first, second and third effector sequence may each comprise a sequence selected from any 10 or more contiguous nucleotides within a sequence from the group consisting of SEQ ID NOS: 1-27, or alternatively, each effector sequence may also be a variant of SEQ ID NOS:1-27, having 1, 2, 3, 4 or 5 nucleotide variations. 
Agens RNK interferencije usmjerene sa DNK (ddRNKI) za inhibiciju ekspresije jedne ili više ciljnih sekvenci u jednom ili u više gena virusa hepatitisa B (HBV), ddRNKi agens koji sadrži, u smjeru 5* do 3": prvu efektorsku sekvencu dužine od najmanje 17 nukleotida; sekvencu komplementa prve efektorske sekvence; drugu efektorsku sekvencu dužine od najmanje 17 nukleotida; i sekvencu komplementa druge efektorske sekvence; pri čemu je svaka efektorska sekvenca najmanje 85% komplementarna predviđenom transkriptu ciljne sekvence i pri čemu najmanje jedna od efektorskih sekvenci sadrži bilo kojih 10 ili više susjednih nukleotida sekvence navedene u SEQ ID NO: 9.
The compounds described in the present invention could be used in combination with suitable anti-inflammatory agents. 
Spojevi opisani u prikazanom izumu mogu se upotrijebiti u kombinaciji sa prikladnim protuupalnim sredstvima.
is independently selected from the group consisting of chloro, fluoro, bromo, cyano, and methoxy; 
R, je neovisno odabrana iz skupine koju čine fluoro, kloro, bromo, metil, trifluorometil, cijano, metoksi, i N(CH3),.
According to the present invention, the compound having general formula (II) is dissolved or suspended in at least one polar or apolar organic solvent, or in a mixture thereof. 
(II) otopljenog ili suspendiranog u najmanje jednom organskom otapalu, s tetrafluoretilenom u prisutnosti vode i anorganske baze kako bi se dobilo navedeni tetrakonazol formule (1) ili jedan od njegovih optički aktivnih izomera.
a DSC thermogram substantially similar to the one set forth in Figure 19; or 
termogram termo-gravimetrijske analize (TGA), sličan onome koji je prikazan na Slici 11; ili
Further, pneumatic or hydraulic actuators are subject to variations in performance by changes in air pressure, fluid flow, changes in machine temperature, lubrication and friction. 
Nadalje, pneumatski ili hidraulički aktuatori su podložni oscilacijama u radu zbog promjene u pritisku zraka, protjecanju tekućine, promjena temperature stroja, podmazivanja i trenja.
The liquefied gas treatment system may further include a cooler configured to cool the BOG, which is liquefied by the heat exchanger and is supplied to the decompressing means, by exchanging heat with the liquid component of the BOG which is decompressed to the gas-liquid mixed state while passing through the decompressing means. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se plinovitu komponentu vraćenu u skladišni spremnik (11) ispušta iz skladišnog spremnika zajedno s otparenim plinom nastalim u skladišnom spremniku, te šalje u kompresor (13,13a,13b).
A compound according to [1], a salt thereof or a hydrate of the foregoing, wherein R1 represents a group represented by the formula —N(CH3)R11i, wherein R11j represents 1-methylpiperidin-4-yl or 1-ethylpiperidin-4-yl. 
Spoj prema zahtjevu 1, njegova sol ili hidrat navedenog, naznačen time da R' predstavlja skupinu prikazanu sa formulom -N(CH;)R''i, pri čemu R''i predstavlja 1-metilpiperidin-4-il ili 1-etilpiperidin-4-il.
A method according to claim 1, wherein the compound is a compound of the following formula, or a pharmaceutically acceptable salt thereof: 
Sastav, naznačen time, da obuhvaća spoj u skladu s bilo kojim od zahtjeva 1 do 33, i farmaceutski prihvatljiv nosač ili razrjeđivač.
b.) reacting a compound of formula II, -wherein R represents C1-4 alkyl except tert-butyl group- by alkalic hydrolysis to give a compound of formula III thereafter reacting with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or b.) reacting a compound of formula III with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or 
S0,0H, il nakon toga reagiranje s organskom ili anorganskom bazom za tvorbu soli, eliminirajući acetonidnu skupinu i reagiranje s kalcij-kloridom u bazi, ili t>& b) reagiranje spoja formule III s organskom ili anorganskom bazom za tvorbu soli, eliminirajući acetonidnu skupinu i reagiranje s kalcij-kloridom u bazi; ili 5 C) reagiranje soli spoja formule ITI
A compound of general formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof R-X-Y-ONO2 (I) wherein R is the prostaglandin residue of Travoprost of formula (II): 
Spoj opće formule (I) ili njegova farmaceutski prihvatljiva sol ili njegov stereoizomer [image] naznačen time da R jest prostaglandinski ostatak formule (II):
Use of Claim 62, wherein the monoclonal antibody or monoclonal antibody fragment is pegylated. 
Uporaba u skladu sa zahtjevom 62, naznačena time, da monoklonsko antitijelo ili fragment monoklonskog antitijela je pegiliran.
iv) benzyl optionally substituted with halogen or alkyl optionally substituted with one to three halogens, cycloalkyl, vi) cycloalkylmethyl, 
cikloalkil, vi) cikloalkilmetil, vii) naftil, viii) piridilmetil, izborno supstituiran s alkilom, izborno supstituiranim s jednim do tri halogena, ix) tienil,
Each of the first and second arms can be multivalent. 
(32) Datum podnošenja prve prijave: 30.03.2007.
Patent application no. 
Broj europske prijave patenta:
Oxalylchloride (2M in dichloromethane, 12 mL) was added slowly to the stirred suspension. 
Oksalilklorid (2M u diklorometanu, 12 ml) se polagano doda u promiješanu suspenziju.
reacting Compound VI with 1-protected 2,2-dimethylpiperazine (IX), wherein PG is a protection group, thereby obtaining a compound of formula X; and 
- >< reakciju Spoja VI s 1-zaštićenim 2,2-dimetilpiperazinom (LX), gdje je PG zaštitna skupina, čime se dobiva spoj formule X; i
The pharmaceutical composition according to claim 19, wherein said composition is in the form of a cream, gel, suspension, ointment, paste, dispersion or emulsion. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 19, naznačen time što je navedeni pripravak u obliku tablete, kapsule, praška, peleta, suspenzije, emulzije, kreme, gela, masti ili paste.
The process of claim 6, wherein less than 10 ppm of 14-hydroxycodeinone is present following step (iv). 
Postupak prema zahtjevu 1, naznačen time da rezultantni sastav oksikodon hidroklorida sadrži 14-hidroksikodeinon u količini manjoj od 10 ppm.
The compounds of the present invention may generally be utilized as the free acid or free base. 
Spojeve prema ovom izumu općenito se može upotrijebiti kao slobodne kiseline ili slobodne baze.
a medicament dispensing mechanism for opening the blister pockets (3) of the blister pack, the medicament dispensing mechanism comprising means for peeling the cover sheet (7) away from the base sheet (5) of the blister pack (1); 
mehanizam raspršivanja lijeka za otvaranje džepova blistera (3) pakiranja blistera, mehanizam raspršivanja lijeka obuhvaća sredstvo za odvajanje pokrovne plohe (7) od bazne plohe (5) pakiranja blistera (1);
A humanized or chimeric CD37-specific immunoglobulin binding protein, comprising: 
Humanizirani CD37-specifični vezni protein obuhvaća:
is independently selected from CR3; and N; 
je neovisno odabran od CR3; i N;
It is sufficient to only use one bonding spot or bonding area as the bond is used to prevent losing the inner cup during handling the container for assembly, packaging, nesting or the like. 
Dovoljno je iskoristiti samo jednu točku spajanja ili samo jedan predio spajanja, budući da se oni koriste samo da spriječe pomicanje unutarnje čaše za vrijeme rukovanja spremnikom radi njegovog sastavljanja, pakiranja, umetanja ili tome slično.
The residue was purified by chromatography on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 100/0 to 70/30 to give 0.310g (72%) of pure product as grey solid. 
Ostatak se pročisti kromatografijom na silikagelu, uz eluiranje smjesom diklormetan/metanol, u odnosima od 100/0 do 70/30 do givni 0,310 g (72 %) čistog produkta u obliku sive krutine,
a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of acidic species of Adalimumab after storage at 25°C for 3 to 6 months of less than 40 %; 
(c) tekuća vodena farmaceutska formulacija koja sadržava terapeutski učinkovitu količinu Adalimumaba u puferiranoj otopini koja sadržava L-histidin i citrat, navedena formulacija ima pH od 5 do 5,5 i ima sadržaj kiselih vrsta Adalimumaba, nakon skladištenja pri 25 *C tijekom 3 do 6 mjeseci, manje od 40 %;
The column capacity was also similar in all the three resin batches (about 2 mg r-hIL-18BP/ml resin, Table 2). TABLE 2 
Kapacitet kolone je također bio sličan za sve tri šarže smole (otprilike 2 mg r-hIL-18BP / ml smole, Tablica 4).
A crystalline form of the compound according to claim 4, wherein the crystalline form has XRPD peaks with a method using Cu anticathode at, at least two of 2 theta angles: 7.75, 10.13, 17.03, 17.16, 18.39, 21.33, and 21.88. 
Kristalni oblik spoja prema zahtjevu 4, naznačen time da kristalni oblik ima XRPD vrhove uz postupak koji koristi Cu antikatodu kod, barem dva od 2 theta kutova: 7.75, 10.13, 17.03, 17.16, 18.39, 21.33, 1 21.88.
The method of claim 8, wherein the nucleotide sequence that is complementary to the target sequence of the target DNA is 15-25 nucleotides (nt) long. 
segment koji cilja na DNK, te koji obuhvaća nukleotidnu sekvencu koja je komplementarna ciljanoj sekvenci u ciljanoj DNK; i
A third process (G) according to the invention comprises carrying out a process selected from processes (A) to (F) followed by interconversion of one or more functional groups. 
Treći postupak (C) sastoji se u provedbi postupka kojeg sc bira između postupaka (A) i (B), uz naknadnu interkonverziju jedne ili više funkcionalnih skupina.
This need for more stable forms of omeprazole is apparent when considering the often considerable time periods involved from the synthesis of the active substance through its incorporation in pharmaceutical preparations, distribution of the finished product to pharmacies etc. 
Ova potreba za stabilnijim oblicima omeprazola postaje očigledna kada se uzmu u obzir često znatni periodi vremena obuhvaćeni od sinteze aktivne supstancije preko njene inkorporacije u farmaceutske kompozicije, distribucije gotovog proizvoda u ljekarne itd.
The compounds of the formula (I) are primary or secondary amines and in one method they can be prepared by the removal of the amino-protecting group from the corresponding amino-protected dihydropyridines. 
Spojevi formule (I) su primarni ili sekundarni amini i postupkom prema izumu mogu se načiniti odvajanjem amino-zaštitne grupe s odgovarajućih amino-zaštićenih dihidropiridina.
The immunogenic composition of claim 8, further comprising at least one active immunogenic component derived from a pathogen other than paramyxovirus. 
Imunogcena smjesa prema patentnom zahtjevu 8, koja dalje sadrži najmanje jednu aktivnu imunogenu komponentu porijeklom od patogena osim paramiksovirusa.
1, where in the front wall 8 a cut-out 20 is placed. 
Ic, gdje je u udubljenom rubu 17 napravljen otvor 20.
A compound of any of the following formulae: wherein R1 is selected from the group consisting of OR2 and NR3R4, and R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, and heteroaryl groups. 
HR P20100218 T1 gdje R, se bira iz skupine koju čine OR> i NR:R., gdje svakog od R2, Ra i Ra se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine, gdje:
producing the antibody of the IgG class in monomeric form by applying a solution to the chromatographic material comprising poly (ethylene glycol) and glycine and thereby desorbing/eluting the antibody of the IgG class in monomeric form from the chromatographic material, whereby the poly (ethylene glycol) has a concentration of from about 0.5 % to 20 % by weight and the glycine has a concentration of from about 0.5 % to 40 % by weight. 
- proizvodnja protutijela IgG-razreda u monomernom obliku primjenom otopine koja sadrži poli(etilenglikol) i sorbitol na kromatografski materijal, te time desorbiranje / eluiranje protutijela IeG- razreda u monomernom obliku iz kromatografskog materijala, pri čemu poli(etilenglikol) ima koncentraciju od 10 masenih % i sorbitol ima koncentraciju od 5 masenih % do 20 masenih %.
The process of claim 5, wherein said basic conditions comprise a base selected from hydroxide or alkoxide base. 
Postupak prema zahtjevu 5, naznačen time, da navedeni bazični uvjeti obuhvaćaju lužinu odabranu od hidroksidne baze ili alkoksidne baze.
forming a salt with an optically pure chiral acid, separating the salts of the two diastereoisomers by fractional crystallisation and then releasing the dihydrotetrabenazine from the salt; or 
(ii) formiranjem soli s optički čistom hiralnom kiselinom, odijeljivanjem soli dvaju dijastereoizomera frakcijskom kristalizacijom i zatim oslobađanjem dihidrotetrabenazina iz soli; ili
Preferably, disorders associated with IRAK are selected from Rheumatoid Arthritis Psoriatic arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Lupus nephritis, Ankylosing Spondylitis, Osteoporosis, Systemic sclerosis, Multiple Sclerosis, Psoriasis, Type I diabetes, Type II diabetes, Inflammatory Bowel Disease (Cronh's Disease and Ulcerative Colitis), Hyperimmunoglobulinemia D and periodic fever syndrome, Cryopyrin-associated periodic syndromes, Schnitzler's syndrome, Systemic juvenile idiopathic arthritis, Adult's onset Still's disease, Gout, Pseudogout, SAPHO syndrome, Castleman's disease, Sepsis, Stroke, Atherosclerosis, Celiac disease, DIRA (Deficiency of IL-1 Receptor Antagonist), Alzheimer's disease, Parkinson's disease, Cancer. 
Spoj prema zahtjevu 7 naznačen time da je bolest odabrana iz skupine koju čine reumatoidni artritis, psorijazni artritis, osteoartritis, sistemski eritemski lupus, lupusni nefritis, ankilozirajući spondilitis, osteoporoza, sistemska skleroza, multipla skleroza, psorijaza, dijabetes tipa I, dijabetes tipa IL, upalna bolest crijeva (Crohnova bolest i ulcerozni kolitis), hiperimunoglobulinemija D i sindrom periodične groznice, periodični sindromi vezani za kriopirin, Schnitzlerov sindrom, sistemski juvenilni idiopatski artritis, Stillova bolest odrasle dobi, giht, pseudogiht, SAPHO sindrom, Castlemanova bolest, sepsa, moždani udar, ateroskleroza, celijakija, DIRA (nedostatak antagonista IIL-1 receptora), Alzheimerova bolest, Parkinsonova bolest, rak.
Use of a compound of formula (I) according to any of claims 1 to 7, or a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers; for the preparation of a medicament for the treatment of a disorder or disease in a subject mediated by CETP or responsive to inhibition of CETP. 
Uporaba spoja formule (I) prema bilo kojem od zahtjeva 1 do 4, ili njegove farmaceutski prihvatljive soli; ili njegovog optičkog izomera; ili mješavine optičkih izomera; naznačena time, da je za proizvodnju lijeka za liječenje poremećaja ili bolesti, pri čemu je poremećaj ili bolest odabrana iz skupine koju čine hiperlipidemija, arterioskleroza, = ateroskleroza, = periferalna - vaskularna bolest, = dislipidemija, - hiperbetalipoproteinemija, hipoalfalipoproteinemija,
For a review of the pharmacology of the gastric acid pump (the H+, K+-ATPase), see Sachs et al. (1995) Annu. 
Pregledne radove o farmakologiji želučanih kiselinskih pumpi (H*, K*-ATPaza) vidi u Sachs i sur, (1995) Annu.
sending electronic data measured by the sensors to the tool; 
slanja elektroničkih podataka o stanjima vozila izmjerenih senzorima (50) u alat (80;160);
1Equivalent to 50 mg of valganciclovir (as free base) on a dry basis. 
' ekvivalent za 50 mg valganciklovira (kao slobodna baza) na suhoj podlozi